This study aimed to determine peripheral blood mononuclear cells ' (PBMC) 
INTRODUCTION
Parvovirus B19 (B19) is a non-enveloped virus with a linear single-stranded genomic DNA. In spite of its small size, B19 is associated with a wide spectrum of diseases in humans, including autoimmune diseases Servant-Delmas et al., 2010; Rogo et al., 2014; Page et al., 2015) . The B19 genome encodes three major proteins: two capsid proteins VP1 (84 kDA) and VP2 (58 kDA), the non-structural protein NS1 (77 kDA), and two small polypeptides (7.5 and 11 kDA). The capsid proteins VP1 and VP2 are almost identical and differ only in an additional 227 amino acids at the amino terminus of VP1 -the so-called VP1-unique region (VP1u) (Heegard and Brown, 2002; Rogo et al., 2014) . The VP1u region is exposed to the surface of viral capsid and contains an immunodominant site with several linear epitopes that underline its importance for humoral immune response (Rosenfeld et al., 1992; Saikawa et al., 1993) . The virus-specific humoral response is well documented, while data on cellular immune response are limited. In 1996, Poblotcky et al. determined cellular immune response against recombinant VP1, VP2, VP1u and NS1 proteins in remotely infected donors and showed that seropositive individuals respond to at least one of the capsid proteins and demonstrated that CD4+ T lymphocytes are the major population of reactive cells (von Polotzki et al., 1996) . The important role of cellular immunity in controlling of B19 replication was further supported by Franssila et al. (2001) , who reported stimulation of proliferation of CD4+ T cells by B19 VP1/2 capsids in recently PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 70 (2016) , No. 4 (703), pp. 175-181. DOI: 10.1515 /prolas-2016 and remotely infected persons (Franssila et al., 2001) . In 2004, the same team showed that B19 VP1 contains an important B-cell epitope and that VP2 is the major target for B19 specific T helper cells during years after natural infection (Franssila and Hedman, 2004) . Lindner et al. investigated T cell responses directed against VP1u region in peripheral blood lymphocytes of donors using stimulation of peripheral blood nuclear cells (PBMC) with autologous B cells producing VP1u. All persons with recent, acute or persistent B19 infection had significant numbers of interferon-gamma secreting lymphocytes while in PBMC of donors with past B19 infection and seronegative individuals, interferon-gamma secreting lymphocytes were not detected (Lindner et al., 2005) . T-cell response in relation to peptide level was determined in healthy seropositive individuals (past infection) and persistently infected persons (with B19 DNA detected in bone marrow during a follow-up period from 2 to 8 years) using 210 overlapping peptides representing entire NS1 and VP1 proteins. In this study, remotely infected individuals had discordant distribution of cellular immune response compared to persistently infected persons. Healthy seropositive individuals had significantly more frequent response to NS1 than to VP1 peptides, while in persistently infected persons more frequent response to VP1 than to NS1 was observed . reported on a study of anti B19 CD4+ T-cell immune responses among remotely infected and acutely infected persons with acute arthropathy using a set of 70 overlapping 20-mer peptides covering VP1/VP2 proteins. This study showed that both acutely and remotely infected persons have broad CD4+ responses, however, the vast majority of acute and remotely infected persons respond to epitope LASEESAFYVLEHSSFQLLG .
In the present study we investigated the frequency and quickness of B19 specific PBMC proliferative response to the virus and VP1/VP2 peptide LASEESAFYV-LEHSSFQLLG in rheumatoid arthritis patients and apparently healthy individuals, and tested the possible effect of methotrexate therapy on B19 specific proliferative response.
MATERIALS AND METHODS
Subjects. 52 RA patients and 25 sex and age matched healthy individuals (control group) were enrolled in this study. 45 of 52 RA patients and 24 of 25 in control group individuals were females. The mean age of RA patients was 56.06 ± 1.54 (range 20-82) years and of the control group individuals -55.48 ± 2.62 (range 26-82) years. Specimens from RA patients and control group individuals were collected at the same time. RA patients were recruited from the Rîga East University Hospital Clinic "Linezers" and Clinic "Gaiïezers". All patients had fulfilled the 1987 or 2010 American College of Rheumatology classification criteria for RA (Arnett et al., 1988; Aletaha et al., 2010) . For RA diagnosis setting plain radiography was used (van der Heijde, 1996) . Magnetic resonance imaging was used to determine early changes and erosions in wrists (Moller et al., 2008) . Staging was based on Venables and Wheeless recommendations (Wheeless, 2012; Venables and Maini, 2013) . The study was approved by the Ethics Committee of the Rîga Stradiòð University and all participants gave their informed consent prior to the examination.
Detection of anti-B19 IgM and IgG class antibodies. Virus specific IgG and IgM class antibodies were detected using the recomLine Parvovirus B19 IgG and IgM test (Microgen, Germany) according to manufacturer's recommendations.
Detection of B19 DNA sequences. The presence of B19 genomic sequences was detected by nested polymerase chain reaction (nPCR). DNA was purified from the peripheral blood leukocytes (PBL) and cell-free blood plasma by proteinase K digestion overnight and standard phenol-chloroform extraction technique. To assure quality of the PBL DNA and to exclude contamination of plasma DNA by cellular DNA, PCR was performed with primers that recognized the 200-bp fragment of the beta-globin gene. B19 NS1 nPCR was performed as described previously (Barah et al., 2001) .
Determination of PBMC proliferative activity. PBMC were isolated from heparinized blood by Ficoll-Hypaque centrifugation (400´g, 30 min) and were washed twice in PBS. The proliferative activity of PBMC was estimated on the 3 rd and 6 th days by the incorporation of 3 H-thymidine into the cells cultivated in the presence of B19 (final concentration -10 6 viral genomes/ml) or VP1/VP2 B19 peptide LASEESAFYVLEHSSFQLLG (Caslo Laboratory ApS, Denmark) at final concentration 10 µg/ml (27). Peripheral blood serum of a highly positive individual was used as the B19 containing material with the viral load calculated by real-time PCR. PBMC were isolated from heparinised blood by Ficoll-Hypaque density gradient centrifugation, washed in RPMI-1640 medium (GIBCO), centrifuged and re-suspended in RPMI-1640 with 10% foetal bovine serum supplemented with penicillin (10 5 U/L) and streptomycin (100 mg/L) (GIBCO). PBMC were seeded into 9-12 wells of two 24-well plates at concentration 1 × 10 6 cells per well. For each specimen 3-4 wells were used. On the 3 rd or 6 th day of cultivation, 2 µCi/well of 3 H-thymidine (25 Ci/mmol, Amersham, England) were added and the cells were incubated for 4 hours. Then the cells were collected and transferred to Millipore filters (diameter of pores 1.5 µm). Filters were washed twice with PBS and three times with 5 ml of 5% Trichloroacetic acid to precipitate DNA. The DNA was fixed by 1 ml of 96% ethanol and air dried at 37°C. 
RESULTS
The radiological examination of RA patients showed that 4 of 52 RA patients had the I radiological stage of RA , 13 patients had the II stage, and 35 patients had erosive arthritis with III stage (33 patients) and IV (2 patients) radiological stages. The majority of the patients had prolonged duration of the disease. In the RA patients with I, II, III, and IV radiological stages, the mean disease duration was 3.0 ± 2.0, 4.2 ± 0.96 10.5 ± 1.5 and 34.5 ± 24.5 years, respectively. Disease duration up to one year was observed in 12 of 52 patients. In three of them, bone erosions were revealed within 3-11 months after appearance of the disease clinical symptoms. th day of cultivation, PBMC of 63.5% (33/52) of RA patients and 32.0% (8/25) of healthy individuals responded to B19 antigens (p = 0.01436). Analysis of PBMC response to B19 antigens depending on the presence of B19 infection markers showed that the lymphocytes of all RA patients (4/4) and all control group persons (6/6) without B19 markers did not respond to B19 antigens. The PBMC of both control group persons with active B19 infection (B19 DNA in plasma and/or IgM antibodies) and 74.1% (10/14) RA patients with the active virus infection reacted to B19 antigens (virus and/or VP1/VP2 peptide) by proliferation on the 3 rd day. Among RA patients, PBMC proliferative response to B19 antigens on the 3 rd day was detected also in 44.8% (13/29) remotely infected patients who had IgG class antibodies only, while in the control group, no response was found in remotely infected persons on the 3 rd day (p = 0.00071). On the 6 th day, PBMC proliferative response to B19 antigens among remotely infected persons was detected in 68.9% (20/29) RA patients and 41.1% (6/17) control group persons, respectively (p = 0.0347). In RA patients who had IgG class antibodies and the B19 genomic sequence in peripheral blood leukocytes (latent stage of persistent infection), PBMC proliferation in response to B19 antigens (virus and/or VP1/VP2 peptide) was observed in 40.0% (2/5) and 80.0% (4/5) individuals on the 3 rd and 6 th days, respectively. In the control group, the latent stage of persistent virus infection was not detected. PBMC proliferative response to B19 VP1/VP2 peptide among RA patients with active infection was detected in 64.2% (9/14) and 57.1% (8/14) individuals on the 3 rd and 6 th days, respectively. In the control group, active B19 infection PBMC proliferation in response to this peptide was observed in both of the individuals, but on the 6 th day only. In remotely infected RA patients, the proliferative response to B19 VP1/VP2 peptide was detected in 27.5% (8/29) and 24.1% (7/29) patients on the 3 rd and 6 th days, respectively, while in the remotely infected control group, PBMC proliferation in response to the B19 peptide was found in 35.2% (6/17) cases on the 6 th day only. PBMC proliferative response to the B19 peptide in RA patients who had IgG class antibodies and B19 genomic sequence in peripheral blood leukocytes was detected in 40.0% (2/5) and 80.0% (4/5) cases on the 3 rd and 6 th days, respectively. Thus, the proliferative response to the VP1/VP2 peptide was observed in RA patients as well as in control group persons, but in RA patients this response was significantly faster than in the control, as on the 3 rd day it was detected in RA patients only (p = 0.009; 0/19 vs 10/34). The PBMC mean stimulation indices of RA patients and control persons are shown in Table 2 . The highest PBMC mean stimulation indices were observed in RA patients and control persons with markers of active infection as well as at with markers of latent stage of persistent infection.
To evaluate the possible effect of methotrexate on B19 specific cellular immune response to the B19 antigens, PBMC proliferative response (mean count per minute) of RA pa- (Fig. 1) . The results showed that in both RA patients groups (with and without methotrexate treatment) the mean count on 6 th day was significantly higher than that on 3 rd day (p < 0.024 and p = 0.006). Significantly higher mean count was observed also on the 3 rd as well as on the 6 th day in RA patients who did not receive methotrexate, compared to the count on the 3 rd and 6 th days in the control group (Fig. 1 ). There were no significant differences in the mean count per min between RA patients with and without methotrexate treatment as well as between RA patients who received methotrexate and the control group. Taking into account the high individual variabilities among RA patients with and without methotrexate treatment, a qualitative analysis was performed, in which RA patients and control group individuals were divided into two subgroups depending on the PBMC mean count. The mean count detected without addition of B19 antigens (negative control) was taken as 100%. One subgroup in each group included patients and control persons who had mean count similar to the negative control (the medium), while the second subgroup included patients and control persons with mean PBMC count higher than in the negative control. In this analysis, significant difference in PBMC proliferative response between RA patients with and without methotrexate therapy on the 3 rd day and on 6 th day were found (Fig. 2) . On the 3 rd day, the number of the patients with high mean count in the group of RA patients receiving methotrexate was significantly lower than in the group of RA patients without methotrexate treatment (p < 0.025), but significantly higher than in the control group (p < 0.0374). The number of the patients with high mean count in the group of RA patients not receiving methotrexate was also significantly higher in comparison with the control group (p < 0.0001). On the 6 th day the number of persons with high mean count in the group of RA patients receiving methotrexate was also significantly lower than in the group of patients without methotrexate treatment (p < 0.012), but similar to the number observed in the control group. Significantly higher number of patients with high mean count revealed in the RA patients without methotrexate treatment compare to the control group on the 3 rd day was also observed on the 6 th day (p < 0.0001). Thus, the highest number of patients with strong PBMC proliferative response to B19 antigens was detected in RA patients who did not receive methotrexate treatment.
DISCUSSION
Association of B19 infection with RA has been demonstrated in several studies, while B19 specific cellular immune response in these patients was unknown (Takahashi et al., 1998; Murai et al., 1999; Stahl et al., 2000; Kozireva et al., 2008; Kakurina et al., 2015) . Although B19 specific cellular immune responses have been investigated very poorly, the existing studies indicate the important role of these responses in the control of acute and persistent B19 infection (Fransilla et al., 2001; Tolfvenstam et al., 2001; Isa et al., 2005; Norbeck et al., 2005; Isa et al., 2006; Streitz et al., 2008) . Recently, using a set of peptides to B19 VP1/VP2 proteins, Kasprowicz et al. (2006) showed that the majority of both acutely (10/12) and remotely (6/7) infected individuals responded to one of the examined VP1/VP2 peptides . Taking into account this observation, we used this peptide in our study to determine the frequency and quickness of PBMC proliferative responses among RA patients and healthy persons with active infection and remotely infected RA pa- tients and healthy persons (control group). In addition, we estimated dependence of B19 specific PBMC proliferative response on the applied therapy, as this aspect had not been previously examined.
The majority of RA patients [64.2% (9/14)] and 100% (2/2) of control group persons with active infection as well as 41.4% (12/29) and 35.2% (6/17) of remotely infected RA patients and control persons, respectively, responded to the applied peptide. Our data on response to the peptide in persons with active B19 infection and remotely infected individuals are consistent with the results of Kasrowicz et al. (2006) . However, the quickness of proliferative response between remotely infected RA patients and control group persons differed. The subset of remotely infected RA patients responded to this peptide on the 3 rd day, while none of the remotely infected control group individuals had responded. Therefore, the PBMC of remotely infected RA patients are able to respond to VP1/VP2 peptide quickly than the PBMC of healthy individuals. Significant differences in proliferative response between RA patients receiving and not receiving methotrexate treatment were observed. Strong PBMC proliferative response to B19 antigens on the 3 rd and 6 th day was more frequently observed in RA patients without methotrexate treatment than in patients receiving methotrexate in different combinations with other drugs. Methotrexate treatment probably has effect on B19 specific PBMC proliferative response. However, on the 3 rd day the number of persons with strong proliferative response in the group of RA patients receiving methotrexate significantly differed from the number in the control group, while on the 6 th day this difference was not observed, which does not allow to make a strong conclusion on the diminishing effect of methotrexate treatment on B19 specific cellular response.
This is the first study identifying the frequency and quickness of PBMC proliferative response to B19 antigens including VP1/VP2 peptide in RA patients with active and remote B19 infection as well as dependence of this response on the applied therapy. We found that RA patients with B19 infection markers responded to the virus antigens faster than healthy persons. Among RA patients receiving methotrexate, the number of individuals with strong response to B19 antigens was significantly lower than among RA patients without methotrexate treatment. 
